Drug search by name

Oritavancin Diphosphate and Bleeding

Result of checking the interaction of drug Oritavancin Diphosphate and disease Bleeding for safety when used together.

Check result:

Oritavancin Diphosphate <> Bleeding

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Oritavancin has been shown to artificially prolong prothrombin time (PT) and international normalized ratio (INR) for up to 12 hours, making the monitoring of the anticoagulation effect of warfarin unreliable up to 12 hours after an oritavancin dose. Oritavancin has no effect on the coagulation system in vivo. Care should be taken when administering this agent to patients at risk for bleeding and they should be monitored for bleeding if concomitantly receiving warfarin. It is recommended to consider a non-phospholipid dependent coagulation test such as a Factor Xa (chromogenic) assay or an alternative anticoagulant not requiring aPTT monitoring for those patients requiring aPTT monitoring within 5 days of oritavancin dosing.

Oritavancin Diphosphate

Generic Name: oritavancin

Brand Name: Orbactiv

Synonyms: Oritavancin

What is Oritavancin Diphosphate?